The latter classification also retains MDS-related molecular findings for patients with bone marrow blasts between 10% and 19%, as described by Lindsley et al., who harbor mutations in splicing factors, STAG2, EZH2, ASXL1, BCOR, and additionally RUNX1 [8,36]. The gene discussed is ASXL1; the disease is myelodysplastic syndrome.